Journals / Journal of the Turkish-German Gynecological Association / 2015 / Cilt: 16 - Sayı: 1

Multiple sclerosis; A disease of reproductive-aged women and the dilemma involving contraceptive methods

Pages
49–53
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review investigates the contraception options and their effects on female MS patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Multiple sclerosis (MS) is an autoimmune disorder characterized by chronic inflammation in the central nerves system.
📊
Key Findings & Data:Because the diseasepredominantly affects women of reproductive ages, having knowledge about contraception options for MS patients can make clinicians providebetter counseling.
💡
Conclusion & Impact:This review investigates the contraception options and their effects on female MS patients.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Multiple sclerosis (MS) is an autoimmune disorder characterized by chronic inflammation in the central nerves system. Because the diseasepredominantly affects women of reproductive ages, having knowledge about contraception options for MS patients can make clinicians providebetter counseling. Although most contraceptive methods are generally accepted as safe and effective in MS patients, recent studies have raisedquestions about their potential adverse effects on the disease. The use of contraceptive methods to avoid unintended pregnancies is crucialin MS patients, particularly during the relapse phase of the disease or the time when the disease is not completely under control. This reviewinvestigates the contraception options and their effects on female MS patients.Providing appropriate contraception options to multiple sclerosis patients will be one of the most challenging issues for clinicians to deal with.Recent studies have raised questions that the use of hormonal contraceptives may at least partly contribute to the rise in incidence of MS inwomen. This review investigates the contraception options and their effects on female MS patients.

🔖

Cite This Article

YILDIRIM, M., YAVUZ, A. F. A., TÜRKYILMAZ, E. (2022). Multiple sclerosis; A disease of reproductive-aged women and the dilemma involving contraceptive methods. Journal of the Turkish-German Gynecological Association, Cilt: 16 - Sayı: 1, 49–53. https://ajindex.com/articles/567549

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000
  2. [CrossRef] 2. Jones J, Mosher WD and Daniels K. Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995, Natl Health Stat Report 2012
  3. http://www.guttmacher.org/media/presskits/contraception-US/ index.html, Contraceptive Use in the United States, March 2014. 4. Vessey MP, Lawless M. The Oxford- Family Planning Association contraceptive study. Clin Obstet Gynaecol 1984
  4. Rachel Seroka, Michelle Uher. Hormonal contraceptives and Multiple Sclerosis Susceptibility. AAN 66 th Annual Meeting Abstract. 2014-08-21. 6. Available online: http://www.clevelandclinicmeded.com/medical- pubs/diseasemanagement/neurology/multiple_sclerosis/ Robert J. Fox. Multiple Sclerosis, June 2014. 7. Helmut Leitner. Multiple sclerosis and progestins: A comment POPART’MUS. J Neurol Sci 2011
  5. [CrossRef] 8. Wilson S. Premenstrual worsening of MS symptoms. Way Ahead 2001
  6. Hellwig K, Schimrigk S, Beste C, Muller T, Gold R. Increase in relapse rate during assisted reproductive technique in patients with multiple sclerosis. Eur Neurol 2009
  7. [CrossRef] 10. Couzinet B, Young J, Kujas M, Meduri G, Brailly S, Thomas JL, et al. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. J Clin Endocrinol Metab 1999
  8. [CrossRef] 11. Lenzi E, PluchinoN, Begliuomini S, Ninni F, Freschi L, Centofanti M, et al. Effects of nomegestrolacetat administration on central and peripheral beta-endorphin and allopregnanolone in rats. J Steroid Biochem Mol Biol 2008
  9. [CrossRef] 12. Leon Sperof, Marc A. Fritz. Klinik Jinekolojik endokrinoloji ve infer- tilite. Sekizincibaskı.2014
  10. Bölüm 25. p.1102 13. Available online: Review: could Mirena cause Multiple Sclerosis. November 2014, http://www.ehealthme.com/ds/mirena/multiple+ sclerosis. 14. Alanso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis, A systematic review. Neurology 2008: 71
  11. [CrossRef] 15. Ito A, BeboJr BF, Matejuk A, Zamora A, Silverman M, Fyfe-Johnson A, Offner H. Estrogen treatment down-regulates TNF-alpha pro - duction and reduces the severity of experimental autoimmune encephalomyelitis cytokine knockout mice. J Immunol 2001
  12. [CrossRef] 16. Matejuk A, Adlard K, Zamora A, Silverman M, Vandenbark AA, O